| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 13.17% | Morgan Stanley | $188 → $229 | Upgrades | Equal-Weight → Overweight |
| 08/04/2023 | 12.68% | Baird | $200 → $228 | Maintains | Outperform |
| 07/21/2023 | 4.27% | Truist Securities | $190 → $211 | Maintains | Buy |
| 07/19/2023 | 0.82% | Stifel | $200 → $204 | Maintains | Buy |
| 05/19/2023 | — | William Blair | Reinstates | → Outperform | |
| 04/17/2023 | -1.16% | Stifel | $196 → $200 | Maintains | Buy |
| 02/23/2023 | -6.1% | Truist Securities | $183 → $190 | Maintains | Buy |
| 12/12/2022 | -7.09% | Morgan Stanley | $187 → $188 | Downgrades | Overweight → Equal-Weight |
| 11/07/2022 | -7.59% | Morgan Stanley | $180 → $187 | Maintains | Overweight |
| 10/11/2022 | -18.46% | Stifel | $162 → $165 | Maintains | Buy |
| 10/11/2022 | -15.99% | Wolfe Research | → $170 | Initiates Coverage On | → Outperform |
| 07/19/2022 | -17.96% | Truist Securities | $167 → $166 | Maintains | Buy |
| 07/18/2022 | -23.4% | Stifel | $168 → $155 | Maintains | Buy |
| 03/01/2022 | -6.6% | Morgan Stanley | $180 → $189 | Maintains | Overweight |
| 01/21/2022 | -15.99% | Berenberg | → $170 | Initiates Coverage On | → Buy |
| 12/03/2021 | -11.05% | Morgan Stanley | → $180 | Initiates Coverage On | → Overweight |
| 09/29/2021 | -22.41% | Baird | $134 → $157 | Upgrades | Neutral → Outperform |
| 01/07/2021 | -41.19% | Baird | → $119 | Downgrades | Outperform → Neutral |
| 05/08/2020 | -31.31% | Stifel | $145 → $139 | Maintains | Buy |
| 04/17/2020 | -35.75% | UBS | $160 → $130 | Maintains | Buy |
| 04/16/2020 | -43.17% | SunTrust Robinson Humphrey | $150 → $115 | Maintains | Buy |
| 02/28/2020 | -25.87% | SunTrust Robinson Humphrey | $157 → $150 | Maintains | Buy |
| 02/28/2020 | -20.93% | UBS | $165 → $160 | Maintains | Buy |
| 01/15/2020 | -18.46% | UBS | $145 → $165 | Upgrades | Neutral → Buy |
| 11/01/2019 | -28.34% | UBS | $134 → $145 | Maintains | Neutral |
| 07/15/2019 | -27.35% | Stifel | $138 → $147 | Maintains | Buy |
| 03/01/2019 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 02/28/2019 | -30.81% | Baird | $123 → $140 | Maintains | Outperform |
| 12/19/2018 | -39.71% | Stifel | $120 → $122 | Upgrades | Hold → Buy |
| 08/16/2018 | -30.81% | UBS | → $140 | Initiates Coverage On | → Neutral |
What is the target price for Curtiss-Wright (CW)?
The latest price target for Curtiss-Wright (NYSE: CW) was reported by Morgan Stanley on August 7, 2023. The analyst firm set a price target for $229.00 expecting CW to rise to within 12 months (a possible 13.17% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Curtiss-Wright (CW)?
The latest analyst rating for Curtiss-Wright (NYSE: CW) was provided by Morgan Stanley, and Curtiss-Wright upgraded their overweight rating.
When is the next analyst rating going to be posted or updated for Curtiss-Wright (CW)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Curtiss-Wright, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Curtiss-Wright was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Curtiss-Wright (CW) correct?
While ratings are subjective and will change, the latest Curtiss-Wright (CW) rating was a upgraded with a price target of $188.00 to $229.00. The current price Curtiss-Wright (CW) is trading at is $202.35, which is within the analyst's predicted range.